Patrick Gan Elected to Inovio Biomedical Board of Directors
SAN DIEGO (Business Wire EON) May 8, 2008 --
Inovio
Biomedical Corporation (AMEX:INO), a
leader in enabling the development of DNA
vaccines using a proprietary electroporation-based
DNA delivery platform, announced today that Patrick Gan was
elected as the Company’s eighth director
at Inovio’s annual general meeting. He joins
re-elected directors James L. Heppell, chairman of the board, Dr.
Avtar Dhillon, president and CEO, and Riaz Bandali, Simon X. Benito,
Tazdin Esmail, Robert W. Rieder and Stephen Rietiker, MD.
Mr. Gan has extensive senior management experience with pharmaceutical
operations throughout Asia and is currently the managing partner of ATP
Capital, a global biotech fund. He has previously been the Asia/Pacific
area director for Novartis, managing director for Glaxo Wellcome in
China and Taiwan, and a senior manager with Roche. He has also been
chief executive of two regional Asian airlines, Tiger Airways and Jett
Air Cargo. He received an honors degree in Pharmacy (BSc) at the
National University of Singapore in 1982, and subsequently obtained an
MBA from the University of Warwick in 1990. He has also attended
executive programs at Harvard Business School and Duke University.
“Patrick Gan brings to Inovio’s
board of directors extensive pharmaceutical operating experience, with
an emphasis on the fast-growing Asia market,”
said Dr. Avtar Dhillon, Inovio’s president &
CEO. “We appreciate ATP’s
continued support as a shareholder of Inovio and welcome Patrick’s
contributions to the Board.”
About Inovio Biomedical Corporation
Inovio Biomedical (AMEX:INO) is focused on developing multiple
DNA-based immunotherapies. Inovio is a
leader in developing human applications of electroporation using
brief, controlled electrical pulses to increase cellular uptake of a
useful biopharmaceutical. Interim human data has shown that Inovio’s
DNA delivery technology can significantly increase gene expression and
immune responses from DNA vaccines. Immunotherapy partners include
Merck, Wyeth, Vical, University of Southampton, Moffitt Cancer Center,
the U.S. Army, National Cancer Institute, and International Aids Vaccine
Initiative. Inovio’s technology is protected
by an extensive patent portfolio covering in vivo
electroporation. More information is available at www.inovio.com.
This press release contains certain forward-looking statements
relating to our plans to develop our electroporation drug and gene
delivery technology. Actual events or results may differ from our
expectations as a result of a number of factors, including the
uncertainties inherent in clinical trials and product development
programs (including, but not limited to, the fact that pre-clinical
results may not be indicative of results achievable from testing in
humans and that results from one study may necessarily not be reflected
or supported by the results of other similar studies), the availability
of funding to support continuing research and studies in an effort to
prove safety and efficacy of Inovio’s
technology as a delivery mechanism, the availability or potential
availability of alternative therapies or treatments for the conditions
targeted by Inovio or its collaborators, including alternatives that may
be more efficacious or cost-effective than any therapy or treatment that
Inovio and its collaborators hope to develop, evaluation of potential
opportunities, issues involving patents and whether they or licenses to
them will provide Inovio with meaningful protection from others using
the covered technologies, whether such proprietary rights are
enforceable or defensible or infringe or allegedly infringe on rights of
others or can withstand claims of invalidity and whether Inovio can
finance or devote other significant resources that may be necessary to
prosecute, protect or defend them, the level of corporate expenditures,
assessments of our technology by potential corporate or other partners
or collaborators, capital market conditions, and other factors set forth
in our Annual Report on Form 10-K for the year ended December 31, 2007
and other regulatory filings. There can be no assurance that any product
in our product pipeline will be successfully developed or manufactured,
or that final results of clinical studies will be supportive of
regulatory approvals required to market licensed products.
Post Comment:
Trackback URL: http://eon.businesswire.com/pingpr.php/WmV0YS1GYWx1LVpldGEtQ291cC1DcmFzLVplcm8=
Bookmark -
Del.icio.us |
Digg |
Furl It |
Spurl |
RawSugar |
Simpy |
Shadows |
Blink It |
My Web
|
